Cargando…

Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas

BACKGROUND: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteina...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Eric T, Alsop, David, Lee, Diana, Tam, Angela, Barron, Loretta, Bloom, Julianne, Gautam, Shiva, Wu, Julian K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2263020/
https://www.ncbi.nlm.nih.gov/pubmed/18186943
http://dx.doi.org/10.1186/1743-8454-5-1
_version_ 1782151429331353600
author Wong, Eric T
Alsop, David
Lee, Diana
Tam, Angela
Barron, Loretta
Bloom, Julianne
Gautam, Shiva
Wu, Julian K
author_facet Wong, Eric T
Alsop, David
Lee, Diana
Tam, Angela
Barron, Loretta
Bloom, Julianne
Gautam, Shiva
Wu, Julian K
author_sort Wong, Eric T
collection PubMed
description BACKGROUND: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteinases. This study determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas. METHODS: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251 glioma cell lines. MMP activity was measured using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. In addition, patients underwent lumbar puncture for CSF sampling at baseline, after 6 weeks (1 cycle), and after 12 weeks (2 cycles), while being treated with a novel chemotherapy regimen of irinotecan, thalidomide, and doxycycline designed to block growth/proliferation, angiogenesis, and invasion. Irinotecan was given at 125 mg/m(2)/week for 4 weeks in 6-week cycles, together with continuous doxycycline at 100 mg twice daily on Day 1 and 50 mg twice daily thereafter. Daily thalidomide dose in our cohort was 400 mg. Tumor progression was monitored by magnetic resonance imaging (MRI). RESULTS: Doxycyline in vitro completely abolished MMP-9 activity at 500 μg/ml while there was only 30 to 50% inhibition of MMP-2 activity. Four patients respectively completed 4, 3, 1, and 2 cycles of irinotecan, thalidomide, and doxycycline. Patient enrollment was terminated after one patient developed radiologically defined pulmonary embolism, and another had probable pulmonary embolism. Although CSF MMP-2 and 130 kDa MMP levels were stable, MMP-9 level progressively increased during treatment despite stable MRI. CONCLUSION: Doxycycline can block MMP-2 and MMP-9 activities from glioma cells in vitro. Increased CSF MMP-9 activity could be a biomarker of disease activity in patients with malignant gliomas, before any changes are detectable on MRI.
format Text
id pubmed-2263020
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22630202008-03-06 Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas Wong, Eric T Alsop, David Lee, Diana Tam, Angela Barron, Loretta Bloom, Julianne Gautam, Shiva Wu, Julian K Cerebrospinal Fluid Res Research BACKGROUND: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteinases. This study determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas. METHODS: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251 glioma cell lines. MMP activity was measured using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. In addition, patients underwent lumbar puncture for CSF sampling at baseline, after 6 weeks (1 cycle), and after 12 weeks (2 cycles), while being treated with a novel chemotherapy regimen of irinotecan, thalidomide, and doxycycline designed to block growth/proliferation, angiogenesis, and invasion. Irinotecan was given at 125 mg/m(2)/week for 4 weeks in 6-week cycles, together with continuous doxycycline at 100 mg twice daily on Day 1 and 50 mg twice daily thereafter. Daily thalidomide dose in our cohort was 400 mg. Tumor progression was monitored by magnetic resonance imaging (MRI). RESULTS: Doxycyline in vitro completely abolished MMP-9 activity at 500 μg/ml while there was only 30 to 50% inhibition of MMP-2 activity. Four patients respectively completed 4, 3, 1, and 2 cycles of irinotecan, thalidomide, and doxycycline. Patient enrollment was terminated after one patient developed radiologically defined pulmonary embolism, and another had probable pulmonary embolism. Although CSF MMP-2 and 130 kDa MMP levels were stable, MMP-9 level progressively increased during treatment despite stable MRI. CONCLUSION: Doxycycline can block MMP-2 and MMP-9 activities from glioma cells in vitro. Increased CSF MMP-9 activity could be a biomarker of disease activity in patients with malignant gliomas, before any changes are detectable on MRI. BioMed Central 2008-01-11 /pmc/articles/PMC2263020/ /pubmed/18186943 http://dx.doi.org/10.1186/1743-8454-5-1 Text en Copyright © 2008 Wong et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wong, Eric T
Alsop, David
Lee, Diana
Tam, Angela
Barron, Loretta
Bloom, Julianne
Gautam, Shiva
Wu, Julian K
Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
title Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
title_full Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
title_fullStr Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
title_full_unstemmed Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
title_short Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
title_sort cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2263020/
https://www.ncbi.nlm.nih.gov/pubmed/18186943
http://dx.doi.org/10.1186/1743-8454-5-1
work_keys_str_mv AT wongerict cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT alsopdavid cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT leediana cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT tamangela cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT barronloretta cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT bloomjulianne cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT gautamshiva cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas
AT wujuliank cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas